Spots Global Cancer Trial Database for Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Official Title: Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate

Study ID: NCT00038168

Conditions

Prostate Cancer

Interventions

Estramustine

Taxol

Study Description

Brief Summary: Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not responded to hormone treatment. A second goal is to find out if the side effects of these drugs can be reversed. The safety of these drugs will also be studied.

Detailed Description: To determine the maximum tolerated dose of intravenous estramustine phosphate combined with Taxol. To estimate the complete and partial response rates to treatments with intravenous estramustine phosphate combined with Taxol in the treatment of hormone-refractory adenocarcinoma of the prostate. To determine the qualitative and quantitative toxicity of the combination of intravenous estramustine phosphate and Taxol.